Sarconeos - Biophytis

Drug Profile

Sarconeos - Biophytis

Alternative Names: BIO 101

Latest Information Update: 17 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biophytis
  • Class Obesity therapies
  • Mechanism of Action Proto-oncogene protein c-mas-1 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Duchenne muscular dystrophy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Muscular atrophy
  • Preclinical Duchenne muscular dystrophy; Obesity

Most Recent Events

  • 15 May 2018 Biophytis expects to receive orphan drug designation in Duchenne muscular dystrophy from EMA in mid 2018
  • 15 May 2018 Sarconeos - Biophytis receives Orphan Drug status for Duchenne muscular dystrophy in USA
  • 28 Mar 2018 Biophytis plans to submit regulatory application to initiate the phase IIb SARA-INT trial for Muscular atrophy in France and Italy in 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top